Epidemiology and outcomes research for MGUS, myeloma and amyloidosis
1Royal Marsden NHS Trust and Parkside Cancer Centre, London, UK.
Abstract:
The epidemiology of plasma cell dyscrasias clearly links to a complicated multi-factorial pathogenic pathway that at the individual patient level gives no clear indication of why the malignant process has occurred but factors in the environment and within the genome give clues and are discussed. MGUS is a pre-malignant disorder characterised by monoclonal plasma cell proliferation in the bone marrow and no end-organ damage; the patients are asymptomatic. Primary amyloidosis is a rare disorder that is characterised by deposition of amyloid fibrils composed of immunoglobulin light chain fragments; symptoms relate to the affected organ. Multiple myeloma is a malignant disease of plasma cells and with improvements in treatment, patients can now expect a doubling of median survival to 5 years, a 20% chance of surviving >10 years and a 50% chance of complete remission (CR), morphological and biochemical. The challenge is now to determine exactly what this means to the individual myeloma patient in terms of benefit, and to society as a whole and this is the basis of 'outcomes research' which is discussed in this review.
Insights
Plasma cell dyscrasias, including MGUS, amyloidosis, and multiple myeloma, involve complex multi-factorial pathways. Outcomes research is crucial for understanding treatment benefits for individual multiple myeloma patients and society.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Plasma cell dyscrasias encompass a spectrum of disorders, from pre-malignant monoclonal gammopathy of undetermined significance (MGUS) to symptomatic primary amyloidosis and malignant multiple myeloma.
- The pathogenesis is multifactorial, involving environmental and genomic factors, yet individual causes remain unclear.
- While treatments have improved survival for multiple myeloma, understanding the true benefit and societal impact requires further investigation.
Purpose of the Study:
- To review the epidemiology and pathogenesis of plasma cell dyscrasias.
- To highlight the characteristics of MGUS, primary amyloidosis, and multiple myeloma.
- To introduce the concept and importance of outcomes research in multiple myeloma.
Main Methods:
- Review of epidemiological data and pathogenic pathways.
- Discussion of clinical characteristics and diagnostic criteria for related disorders.
- Exploration of current treatment advancements and survival statistics in multiple myeloma.
Main Results:
- Plasma cell dyscrasias arise from complex, multifactorial pathways influenced by environment and genome.
- MGUS is a pre-malignant condition, primary amyloidosis involves immunoglobulin light chain deposition, and multiple myeloma is a malignant plasma cell disorder.
- Multiple myeloma patients now have improved median survival, increased long-term survival chances, and higher complete remission rates.
Conclusions:
- Understanding the underlying causes of plasma cell dyscrasias remains a challenge.
- Advances in multiple myeloma treatment have significantly improved patient outcomes.
- Outcomes research is essential to evaluate the real-world benefits of these advancements for patients and society.